BRCA Mutation Clinical Trials

8 recruiting

BRCA Mutation Trials at a Glance

9 actively recruiting trials for brca mutation are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 1 with 3 trials, with the heaviest enrollment activity in Boston, Caen, and Chicago. Lead sponsors running brca mutation studies include Azienda Sanitaria-Universitaria Integrata di Udine, Centre Francois Baclesse, and 858 Therapeutics, Inc..

Browse brca mutation trials by phase

Treatments under study

About BRCA Mutation Clinical Trials

Looking for clinical trials for BRCA Mutation? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new BRCA Mutation trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about BRCA Mutation clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting

Prediction of Germline BRCA 1/2 Genes From Healthy Ovaries

Ovarian CancerBRCA MutationUltrasound Therapy; Complications
Fondazione Policlinico Universitario Agostino Gemelli IRCCS6,465 enrolled1 locationNCT05769517
Recruiting
Phase 1Phase 2

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Breast CancerOvarian CancerEndometrial Cancer+8 more
858 Therapeutics, Inc.120 enrolled14 locationsNCT06395519
Recruiting
Phase 1

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

BRCA MutationBRCA1 MutationBRCA2 Mutation+3 more
Pamela Munster18 enrolled1 locationNCT06177171
Recruiting

The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation.

Prostate CancerBRCA MutationATM Gene Mutation+4 more
Institute of Cancer Research, United Kingdom50 enrolled1 locationNCT05097274
Recruiting
Phase 1

Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors

Breast CancerOvarian CancerProstate Cancer+4 more
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd30 enrolled2 locationsNCT06666270
Recruiting

MEASUREMENT OF CIRCULATING MUTATION BURDEN

Breast CarcinomaGenetic Predisposition to CancerBRCA Mutation+2 more
Centre Francois Baclesse30 enrolled1 locationNCT06792721
Recruiting

Development and Validation of an Ovarian Cancer Risk Prediction Model for Family Members of Ovarian Cancer Probands

Hereditary Breast and Ovarian Cancer SyndromeBRCA Mutations
Peking University Third Hospital10,000 enrolled1 locationNCT07039552
Recruiting
Not Applicable

MiniLap Vs Standard Laparoscopy in Prophylactic Bilateral Salpingo-oophorectomy in BRCA-Mutated Patients

BRCA Mutation
Azienda Sanitaria-Universitaria Integrata di Udine80 enrolled1 locationNCT06831747
Recruiting

Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer

Prostate CancerBRCA MutationCastrate Resistant Prostate Cancer
Santa Chiara Hospital3,000 enrolled2 locationsNCT06783127